Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab With Palbociclib Plus Fulvestrant in HER2+/HR+ Advanced Breast Cancer
NCT04224272Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jun 2020
- Primary completion
- Apr 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of zanidatamab in breast cancer, sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Number of Participants With Dose-Limiting Toxicities at 28 days, Number of Participants Reporting Grade 3 or Higher Treatment-emergent Adverse Events and 1 more. Started Jun 2020; status: completed.
02
Drugs
zanidatamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04224272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224272.